Associations of three metabolic biomarkers with the risk of cardiometabolic multimorbidity: a national prospective study Authors: Yan Jiang, Mengdie Liu, Hua Chen, Fengpei Zhang, Si Liu, Xin Li, Ting Guo, Zhiteng Xiong, Qihui Shen, Xiaoyun Xiong Published: 2026 ABSTRACT AbstractBackgroundMetabolic dysfunction is a key contributor to cardiometabolic diseases (CMD); however, its role in the development of cardiometabolic multimorbidity (CMM) remains insufficiently understood. Using data from the China Health and Retirement Longitudinal Study (CHARLS), this study examined the associations between three metabolic indices and the risk of developing CMM among Chinese adults, namely the triglyceride glucose index (TyG), the cholesterol-high-density lipoprotein-glucose index (CHG), and the C-reactive protein triglyceride glucose index (CTI).MethodsA total of 5,666 participants were included in this study. The associations between the three metabolic indices and incident CMM were estimated using Cox proportional hazards regression models with adjustment for relevant confounders. Restricted cubic spline analyses were performed to evaluate potential nonlinear associations. The discriminative performance of the metabolic indices was assessed using receiver operating characteristic (ROC) curves and the area under the curve (AUC). Subgroup analyses were conducted according to age and sex.ResultsIncident CMM occurred in 473 of 5,666 participants (8.3%). Cox regression analyses showed that higher values of the TyG, CHG, and CTI indices were associated with an increased risk of CMM. Compared with participants in the lowest quartile, those in the highest quartiles of TyG and CTI had substantially higher risks of CMM, with HRs (95% CIs) of 2.10 (1.50–2.94) for TyG Q4 versus Q1 and 2.55 (1.82–3.57) for CTI Q4 versus Q1. In contrast, participants in CHG Q4 did not have a significantly higher risk of CMM than those in Q1, with an HR (95% CI) of 1.12 (0.85–1.48). No significant effect modification by age or sex was observed. ROC analyses indicated that CTI and composite indices incorporating CTI showed relatively better discriminative performance, with AUC values of 0.670 for CTI and 0.671 for the TyG-CTI index.ConclusionsThe three metabolic indices were independently associated with an elevated risk of CMM, with composite indices incorporating CTI showing the strongest discriminative performance. These findings support the use of metabolic indices for early risk stratification and targeted interventions, thereby potentially contributing to healthier aging and reducing the societal burden of CMM.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12944-026-02986-3.Keywords: Cardiometabolic multimorbidity, Triglyceride glucose index, Cholesterol-high-density lipoprotein-glucose index, C-reactive protein triglyceride glucose index, Metabolic indices Introduction Multimorbidity has become a major public health challenge. It is commonly defined as the coexistence of two or more chronic diseases in the same individual [1–4]. Cardiometabolic multimorbidity (CMM), defined as the coexistence of two or more cardiovascular and metabolic conditions [5–7], is associated with higher mortality, poorer clinical outcomes, and reduced quality of life [6, 8]. Approximately 30% of older adults are affected by CMM [9]. In the United States, the prevalence of CMM among adults was 14.4% in 2017–2018, affecting more than 34 million individuals; this prevalence increased with age and reached approximately 42.9% among individuals aged ≥ 80 years [10]. In China, the overall incidence of CMM among women has been reported to be 33.1% [11]. These findings highlight the growing global burden of CMM and the need to better understand its risk factors and predictors. Therefore, identifying effective indicators for predicting CMM is essential for promoting healthy aging and reducing the health burden on families and society. Metabolic dysregulation plays a central role in the development and progression of CMM. Persistent abnormalities in glucose and lipid metabolism, which are commonly observed in individuals with obesity and other cardiometabolic risk factors, may predispose them to multiple cardiometabolic conditions [12]. These disturbances can impair insulin sensitivity, compromise vascular function by reducing endothelial nitric oxide synthase (eNOS) activity and increasing adhesion molecule expression [13, 14], and disrupt energy utilization in peripheral tissues [15]. Together, these processes may form a self-reinforcing cycle that promotes systemic metabolic dysfunction [16–21]. Several composite indices have been proposed to capture different dimensions of metabolic dysfunction and predict the risk of cardiometabolic diseases (CMD). The triglyceride glucose index (TyG) is a widely used indicator of insulin resistance and has been identified as an important factor in the development of CMM [22]. The cholesterol-high-density lipoprotein-glucose index (CHG) reflects lipid and glucose interactions under impaired glucose regulation [23], whereas the C-reactive protein triglycerides glucose index (CTI) integrates glucose, triglycerides, and C-reactive protein, thereby providing a broader assessment of cardiometabolic dysfunction [24, 25]. However, most existing studies have focused primarily on the associations between these indices and individual cardiometabolic diseases, whereas evidence regarding their role in CMM remains limited. In particular, the potential contributions of CHG and CTI to the development of CMM have rarely been examined in population studies. Moreover, comparative evidence evaluating multiple metabolic indices simultaneously in relation to CMM risk remains scarce. Therefore, further research is needed to clarify the relevance of these metabolic indices to CMM and to determine their potential value in identifying individuals at increased risk of developing CMM. Given these gaps, the associations between metabolic factors and CMM remain insufficiently established, particularly in Chinese populations. Using data from the China Health and Retirement Longitudinal Study (CHARLS), this study aimed to examine the associations of the TyG, CHG, and CTI indices with CMM and to evaluate their predictive performance in a Chinese population. Materials and methods Study design CHARLS is a nationally representative longitudinal cohort study of Chinese adults aged 45 years and older [26]. Launched in 2011 as wave 1, CHARLS has completed four follow-up waves, namely waves 2–5 in 2013, 2015, 2018, and 2020. Trained personnel collected sociodemographic, lifestyle, and medical history data using standardized electronic questionnaires during face-to-face interviews. The study was reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [27]. For this analysis, participants with missing data or prevalent CMM at baseline, defined as two or more cardiometabolic diseases, were excluded. Finally, 5,666 individuals with zero or one cardiometabolic disease at baseline were included and followed through waves 2–5. Figure 1 shows the participant enrollment flowchart. Flow chart of inclusion and exclusion criteria of participants Assessment of CMM Diabetes was defined according to the 2005 American Diabetes Association (ADA) criteria or a participant-reported previous diagnosis made by a licensed physician. Heart disease and stroke were identified primarily based on participant-reported physician diagnoses obtained during baseline and follow-up surveys. Participants were classified as having CMM if they had two or more of the following conditions: heart disease, stroke, and diabetes [28]. Data collection At baseline, trained interviewers collected sociodemographic and health information. Physical measurements were conducted by trained healthcare professionals, and body mass index (BMI) was calculated and classified according to the 2025 Chinese guidelines for adults [29]. All participants fasted overnight before venous blood collection, and blood samples were processed by trained staff and analyzed at the central laboratory in Beijing using standardized procedures. Assessment of three metabolic composite indices TyG TyG CHG CHG CTI CTI Statistical analysis Baseline characteristics were compared between participants with and without incident CMM during follow-up. Between-group differences were assessed using parametric tests, nonparametric tests, or chi-square tests, as appropriate. Cox proportional hazards regression models were used to evaluate the associations between the three metabolic indices and incident CMM, and the results were reported as hazard ratios (HRs) with 95% confidence intervals (CIs). To assess multicollinearity, variance inflation factors (VIFs) were calculated for all candidate covariates. Variables with a VIF greater than 5, variables included in the calculation of the exposure indices, and variables considered intermediates on the causal pathway were excluded to improve model stability and interpretability while avoiding overadjustment. Three sequential models were constructed. Model 1 was the crude model and provided unadjusted associations; Model 2 was adjusted for sociodemographic and anthropometric variables to account for general metabolic risk factors; and Model 3 was further adjusted for clinical comorbidities, which are established risk factors for CMM and potential confounders of these associations. These sequential adjustments were used to more accurately estimate the independent associations between the metabolic indices and incident CMM. To further explore potential nonlinear associations, restricted cubic spline analyses were performed, and dose–response curves between the three metabolic indices and CMM risk were plotted. The area under the receiver operating characteristic curve (AUC) was calculated to assess the discriminative performance of the three metabolic indices for CMM. For each combined indicator, the corresponding component variables were entered simultaneously into a logistic regression model with incident CMM status as the dependent variable, and a predicted probability was generated at the indicator-combination level based on the estimated regression coefficients. A predicted probability was generated for each combined indicator and subsequently used as continuous test variables to construct receiver operating characteristic (ROC) curves and calculate AUC values. Subgroup analyses stratified by age and sex were further conducted to examine the consistency of the associations across different population subgroups. Statistical analyses were performed using SPSS version 25.0 and R software, and GraphPad Prism version 7.0 was used for graphing. Statistical significance was defined as a two-sided P < 0.05. Results Baseline characteristics of study participants A total of 5,666 participants from the 2011 CHARLS cohort were included in the present study. The mean age was 57.88 ± 8.84 years; women slightly outnumbered men, and most participants lived in rural areas. During the subsequent 9-year follow-up period, 473 participants developed incident CMM (8.3%). Compared with participants who did not develop incident CMM, those who developed incident CMM were older (59.39 ± 7.89 vs. 57.75 ± 8.91 years) and had a higher proportion of women (62.6% vs. 55.9%). Participants who developed incident CMM also had significantly higher anthropometric measures, suggesting greater adiposity. Both systolic and diastolic blood pressure levels were significantly higher among participants who developed incident CMM. Baseline data showed that participants who developed incident CMM had a higher prevalence of cardiometabolic and organ-related conditions than those who did not. Their blood biomarkers also suggested less favorable metabolic and inflammatory profiles. In addition, the TyG, CHG, and CTI indices were all significantly higher among participants who developed incident CMM, indicating increased cardiometabolic risk and systemic inflammation. The baseline characteristics of the study participants are summarized in Table 1. Figure 2 presents the distributions of the TyG (A), CHG (B) and CTI (C). Table 1Baseline characteristics of the study participants according to cardiometabolic multimorbidityVariableTotalNon-CMMCMM P N (%)56665193473Gender, n(%) Male2466 (43.5%)2289 (44.1%)177 (37.4%)0.005 Female3200 (56.5%)2904 (55.9%)296 (62.6%)Age (years)57.88 ± 8.8457.75 ± 8.9159.39 ± 7.89< 0.001BMI, kg/m2, n(%) < 243327 (58.7%)3151 (60.7%)176 (37.2%)< 0.001 ≥ 242339 (41.3%)2042 (39.3%)297 (62.8%)WHtR0.54 ± 0.110.53 ± 0.110.57 ± 0.09< 0.001Drinking, n(%)2145 (37.9%)1974 (38.0%)171 (36.2%)0.424Smoking, n(%)2057 (36.3%)1899 (36.6%)158 (33.4%%)0.171Married, n(%) Yes5150 (90.9%)4724 (91.0%)426 (90.1%)0.512 Others516 (9.1%)469 (9.0%)47 (9.9%)Education, n(%) Below primary2725 (48.1%)2484 (47.8%)241 (51.0%)0.608 Primary school1252 (22.1%)1153 (22.2%)99 (20.9%) Middle school1143 (20.2%)1055 (20.3%)88 (18.6%) High school or above546 (9.6%)501 (9.6%)45 (9.5%)Residence, n (%) Urban1805 (31.9%)1641 (31.6%)164 (34.7%)0.170 Rural3861 (68.1%)3552 (68.4%)309 (65.3%)SBP, mmHg127.42 ± 20.36126.84 ± 20.15133.79 ± 21.55< 0.001DBP, mmHg74.65 ± 11.9274.40 ± 11.8377.42 ± 12.51< 0.001Basal chronic disease, n (%) Hypertension2518 (44.4%)2213 (42.6%)305 (64.5%)< 0.001 Diabetes698 (12.3%)562 (10.8%)136 (28.8%)< 0.001 Stroke71 (1.3%)56 (1.1%)15 (3.2%)< 0.001 Heart disease502 (8.9%)386 (7.4%)116 (24.5%)< 0.001 Cancer38 (0.7%)34 (0.7%)4 (0.8%)0.847 Dyslipidemia514 (9.1%)400 (7.7.%)114 (24.1%)< 0.001 Kidney diseases286 (5.0%)243 (4.7%)43 (9.1%)< 0.001 Liver diseases184 (3.2%)151 (2.9%)33 (7.0%)< 0.001 Lung diseases465 (8.2%)409 (7.9%)56 (11.8%)0.003Serum parameters FPG, mg/dL107.30 ± 29.76102.62 ± 19.40112.59 ± 37.10< 0.001 HbA1c (%)5.25 ± 0.735.12 ± 0.465.40 ± 0.89< 0.001 TC, mg/dL194.30 ± 38.00193.48 ± 37.77203.28 ± 39.39< 0.001 TG, mg/dL127.46 ± 93.58125.02 ± 92.78154.16 ± 98.13< 0.001 LDL-C, mg/dL117.76 ± 34.67116.39 ± 33.45118.45 ± 35.890.045 HDL-C, mg/dL51.66 ± 14.9852.87 ± 14.8550.50 ± 15.15< 0.001 CRP, mg/L0.95 (0.53, 1.95)0.92 (0.52,1.90)1.41 (0.72,2.58)< 0.001 BUN, mg/dL15.60 ± 4.4215.65 ± 4.4615.65 ± 4.430.987 Serum creatinine, mg/dL0.77 ± 0.180.76 ± 0.180.77 ± 0.180.664 Hemoglobin, g/dL14.39 ± 2.2414.34 ± 2.2714.41 ± 2.130.314 Uric acid, mg/dL4.34 ± 1.194.32 ± 1.184.34 ± 1.200.533TyG8.64 ± 0.638.61 ± 0.628.97 ± 0.67< 0.001CHG13.11 ± 0.4213.11 ± 0.4213.17 ± 0.460.002CTI8.68 ± 0.818.64 ± 0.809.13 ± 0.82< 0.001Data were expressed as the mean±standard deviation (SD) or median (upper and lower quartiles) or number (proportion)Abbreviations CMM cardiometabolic multimorbidity, BMI body mass index, WHtR waist-to- height ratio, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, HbA1c glycated haemoglobin, TC total cholesterol, TG triglycerides, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, CRP c-reactive protein, BUN blood urea nitrogen, TyG triglyceride-glucose, CHG cholesterol-high-density lipoprotein-glucose index, CTI c-reactive protein-triglycerides-glucose index Baseline characteristics of the study participants according to cardiometabolic multimorbidity Data were expressed as the mean±standard deviation (SD) or median (upper and lower quartiles) or number (proportion) Abbreviations CMM cardiometabolic multimorbidity, BMI body mass index, WHtR waist-to- height ratio, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, HbA1c glycated haemoglobin, TC total cholesterol, TG triglycerides, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, CRP c-reactive protein, BUN blood urea nitrogen, TyG triglyceride-glucose, CHG cholesterol-high-density lipoprotein-glucose index, CTI c-reactive protein-triglycerides-glucose index Distribution of TyG (A), CHG (B), CTI (C) among study participants Associations of TyG, CHG, and CTI indices with CMM risk Cox regression analysis indicated that the TyG, CHG, and CTI indices were associated with the risk of developing CMM in Models 1 and 2. In Model 3, these associations remained statistically significant for the TyG and CTI indices, but not for the CHG index. For each 1-SD increase, the fully adjusted HRs (95% CIs) were 1.30 (1.13–1.51) for the TyG index and 1.29 (1.15–1.45) for the CTI index. In contrast, no statistically significant association was observed between the CHG index and CMM risk (HR = 0.88, 95% CI 0.70–1.10; Table 2). Table 2Cox regression analysis of metabolic biomarkers and risk of incident CMMVariablesModel 1P valueModel 2P valueModel 3P valueTyG Per SD1.97 (1.76, 2.21)< 0.0011.81 (1.60, 2.04)< 0.0011.30 (1.13, 1.51)< 0.001 Q1Reference-Reference-Reference- Q22.05 (1.45, 2.90)< 0.0011.88 (1.33, 2.65)< 0.0011.72 (1.21,2.43)0.002 Q32.64 (1.89, 3.68)< 0.0012.23 (1.59, 3.12)< 0.0011.93 (1.38, 2.71)< 0.001 Q44.26 (3.11, 5.83)< 0.0013.41 (2.47, 4.17)< 0.0012.13 (1.52, 2.99)< 0.001CHG Per SD1.42 (1.15, 1.76)0.0011.43 (1.14, 1.80)0.0020.88 (0.70,1.10)0.248 Q1Reference-Reference-Reference- Q21.01 (0.77, 1.32)0.9391.01 (0.77, 1.33)0.9250.97 (0.74, 1.28)0.853 Q31.04 (0.80, 1.36)0.7731.02 (0.78, 1.34)0.8650.96 (0.74, 1.26)0.782 Q41.39 (1.08, 1.78)0.0101.36 (1.05, 1.75)0.0180.95 (0.72, 1.25)0.706CTI Per SD1.82 (1.65, 2.00)< 0.0011.66 (1.50, 1.84)< 0.0011.29 (1.15, 1.45)< 0.001 Q1Reference-Reference-Reference- Q22.00 (1.39, 2.87)< 0.0011.83 (1.27, 2.63)0.0011.79 (1.25, 2.58)0.002 Q32.88 (2.04, 4.06)< 0.0012.43 (1.72, 3.44)< 0.0012.08 (1.46, 2.94)< 0.001 Q44.96 (3.59, 6.86)< 0.0013.87 (2.77, 5.40)< 0.0012.58 (1.83, 3.65)< 0.001Abbreviations CMM cardiometabolic multimorbidity, BMI body mass index, WHtR waist-to- height ratio, SBP systolic blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, CRP c-reactive protein, TC total cholesterol, TG triglycerides, FPG fasting plasma glucose, HbA1c glycated haemoglobin, TyG triglyceride-glucose, CHG cholesterol-high-density lipoprotein-glucose index, CTI c-reactive prote in-triglycerides-glucose indexModel 1: Unadjusted model. Model 2: Adjusted for gender, age, BMI,, WHtR, SBP, DBP. Model 3: Model 2 further adjusted for hypertension, diabetes, stroke, heart disease, hyperlipidemia, kidney disease, liver disease, lung disease Cox regression analysis of metabolic biomarkers and risk of incident CMM Abbreviations CMM cardiometabolic multimorbidity, BMI body mass index, WHtR waist-to- height ratio, SBP systolic blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, CRP c-reactive protein, TC total cholesterol, TG triglycerides, FPG fasting plasma glucose, HbA1c glycated haemoglobin, TyG triglyceride-glucose, CHG cholesterol-high-density lipoprotein-glucose index, CTI c-reactive prote in-triglycerides-glucose index Model 1: Unadjusted model. Model 2: Adjusted for gender, age, BMI,, WHtR, SBP, DBP. Model 3: Model 2 further adjusted for hypertension, diabetes, stroke, heart disease, hyperlipidemia, kidney disease, liver disease, lung disease When categorized into quartiles, higher TyG levels were associated with an increased risk of CMM. In Model 3, participants in Q2, Q3, and Q4 had significantly higher risks of CMM than those in Q1, with the strongest association observed in Q4 (HR = 2.13, 95% CI: 1.52–2.99). For the CHG index, no significant statistical findings regarding CMM risk were observed in Model 3, either when analyzed per standard deviation increase (HR = 0.88, 95% CI: 0.70–1.10) or across quartiles; the elevated risks observed in Q4 in Models 1 and 2 were attenuated after full adjustment. Higher CTI quartiles were consistently associated with an increased risk of CMM in Model 3. Compared with participants in Q1, those in Q2, Q3, and Q4 had significantly higher risks, with the strongest association observed in Q4 (HR = 2.58, 95% CI: 1.83–3.65). The associations of the three metabolic indices with CMM risk are illustrated in Fig. 3. Incidence of cardiometabolic multimorbidity (CMM) across quartiles of TyG (A), CHG (B), and CTI (C) In the fully adjusted analysis, TyG and CTI independently associated with higher CMM risk, but CHG was not significantly associated after accounting for confounders. Restricted cubic spline analyses In addition, restricted cubic spline (RCS) analyses showed that none of the three metabolic indices had statistically significant overall or nonlinear associations with CMM risk (P for overall > 0.05; P for nonlinearity > 0.05). Specifically, the TyG index showed a gradual increasing trend in CMM risk with increasing TyG levels, although this tendency did not reach statistical significance. The dose–response curve for the CHG index remained relatively flat, suggesting no apparent association with CMM risk. The CTI index showed a slight U-shaped pattern; however, the test for nonlinearity was not statistically significant. Overall, these results suggest that the TyG, CHG, and CTI indices did not show statistically significant dose-response associations with CMM risk in this study. The RCS curves for the three indices are presented in Fig. 4. The RCS analysis of CMM by TyG (A), CHG (B), CTI (C). The model was adjusted for gender, age, BMI,, WHtR, SBP, DBP, hypertension, diabetes, stroke, heart disease, hyperlipidemia, kidney disease, liver disease, lung disease, HDL-C, CRP, TC, TG, FPG, HbA1c Subgroup analyses In subgroup analyses stratified by age and sex, neither age nor sex significantly modified the associations between quartiles of the TyG, CHG, and CTI indices and CMM risk. Specifically, the P values for interaction across age subgroups (< 60 vs. ≥60 years) were 0.976 for TyG, 0.957 for CHG, and 0.981 for CTI. Similarly, the P values for interaction across sex subgroups (male vs. female) were 0.994, 0.639, and 0.628, respectively, indicating no evidence of effect modification. Across both age and sex strata, the estimated hazard ratios for quartiles of each index were generally greater than 1, and no consistent monotonic trends were observed. Overall, the associations of TyG, CHG, and CTI with CMM risk were broadly consistent across subgroups, with no apparent heterogeneity. The results of the subgroup analyses for TyG, CHG, and CTI are shown in Fig. 5. The Subgroup analysis of CMM by TyG (A), CHG (B), CTI (C). The model was adjusted for gender, age, BMI,, WHtR, SBP, DBP, hypertension, diabetes, stroke, heart disease, hyperlipidemia, kidney disease, liver disease, lung disease, HDL-C, CRP, TC, TG, FPG, HbA1c Metabolic indices as predictors of CMM To evaluate the discriminative performance of the three metabolic indices for CMM, ROC analyses were conducted. Among the individual indices, the CTI index demonstrated the highest discriminative performance (AUC = 0.670, 95% CI: 0.645–0.694), followed by the TyG index (AUC = 0.658, 95% CI 0.633–0.682). In contrast, the CHG index showed relatively weak discriminative performance (AUC = 0.537, 95% CI: 0.509–0.566). For combined indices, the TyG–CTI and CHG–CTI combinations yielded slightly higher discriminative performance than the individual indices (AUC = 0.671, 95% CI: 0.646–0.695; and AUC = 0.671, 95% CI 0.646–0.696, respectively). The discriminative performance of the TyG-CHG combination was comparable to that of the TyG index alone (AUC = 0.657, 95% CI 0.632–0.682). All combined models demonstrated statistical significance (P < 0.001). In pairwise comparisons, the TyG–CTI combination significantly outperformed the TyG index alone (P = 0.027), and CHG–CTI performed significantly better than the CHG index alone (P < 0.001). Overall, CTI and composite indices incorporating CTI showed better discriminative performance for CMM than most individual indices, suggesting that metabolic indices may be useful tools for CMM risk assessment (Fig. 6; Table 3). Receiver operating characteristic curves for CMM prediction by TyG, CHG, CTI, CHG-CTI, TyG-CTI, TyG-CHG Table 3Receiver operating characteristic curves test of Three metabolic inflammation-related composite indexes for predicting CMM among study participants TestAUC95% CICutoff valueSpecificitySensitivityP valueP value# TyG0.6580.633–0.6828.4400.4340.789< 0.001- CHG0.5370.509–0.56613.3370.7170.3590.007< 0.001 CTI0.6700.645–0.6948.7450.5930.670< 0.0010.100TyG-CHG0.6570.632–0.682---< 0.0010.789TyG-CTI0.6710.646–0.695---< 0.0010.027CHG-CTI0.6710.646–0.696---< 0.0010.089Abbreviations CMM cardiometabolic multimorbidity, TyG triglyceride-glucose, CHG cholesterol-high-density lipoprotein-glucose index, CTI c-reactive protein-triglycerides-glucose index, TyG-CHG Combined TyG and CHG, TyG-CTI Combined TyG and CTI, CHG-CTI Combined CHG and CTIP value#: comparison of TyG and the other five indices using the DeLong test for correlated ROC curves Receiver operating characteristic curves test of Three metabolic inflammation-related composite indexes for predicting CMM among study participants Abbreviations CMM cardiometabolic multimorbidity, TyG triglyceride-glucose, CHG cholesterol-high-density lipoprotein-glucose index, CTI c-reactive protein-triglycerides-glucose index, TyG-CHG Combined TyG and CHG, TyG-CTI Combined TyG and CTI, CHG-CTI Combined CHG and CTI P value#: comparison of TyG and the other five indices using the DeLong test for correlated ROC curves Discussion In this prospective study, we systematically evaluated the associations of three metabolic indices, namely TyG, CHG, and CTI, with the risk of CMM among Chinese adults. Higher levels of these indices were associated with an increased risk of CMM, and these associations remained generally consistent after adjustment for established cardiometabolic risk factors. Notably, CTI and composite indices incorporating CTI showed better discriminative performance than most individual indices. Subgroup analyses further showed that these associations were broadly consistent across age and sex groups, suggesting limited heterogeneity across demographic subgroups. The TyG index is widely recognized as a surrogate marker of insulin resistance and has been associated with multiple cardiometabolic disorders. It has been shown to predict adverse cardiovascular outcomes in high-risk populations [30, 31], correlate with coronary heart disease in patients with hypertension [32], and show an independent, dose-response association with stroke risk [33]. Moreover, it has shown high sensitivity in predicting diabetes [34], which is consistent with our findings. As a central mechanism underlying metabolic syndrome, insulin resistance contributes to cardiovascular injury through hyperglycemia, dyslipidemia, and elevated blood pressure [35]. At the cellular level, it promotes endothelial and smooth muscle dysfunction [36], oxidative stress [37], lipid metabolic abnormalities [38], and activation of inflammatory pathways [39]. Taken together, these complex mechanisms suggest that measures of insulin resistance alone may not fully capture the diverse metabolic alterations underlying CMM. In this context, composite indices incorporating additional metabolic dimensions may provide complementary information beyond insulin resistance alone. The CHG index extends the TyG framework by integrating lipid-related parameters, thereby providing a broader characterization of metabolic imbalance under conditions of dysregulated glucose metabolism [23]. This feature may enhance its sensitivity to early metabolic alterations that precede overt disease onset. In addition, CTI integrates glucose, triglycerides, and C-reactive protein and may more directly reflect both atherogenic dyslipidemia and inflammatory burden, including alterations in triglyceride-rich lipoproteins, remnant cholesterol, and dysregulated lipoprotein metabolism [24, 25]. These lipid-related abnormalities may contribute directly to atherosclerotic plaque formation and progression and may also promote low-grade inflammation, which can further exacerbate lipid metabolic abnormalities by affecting lipoprotein production and clearance. Consequently, CTI may capture an integrated metabolic burden characterized by lipid dysregulation and inflammation, potentially explaining its more robust and consistent association with CMM. Although the TyG, CHG, and CTI indices showed different patterns of association with CMM risk, their strengths and consistency varied across models. Higher TyG levels were associated with an increased risk of CMM, supporting the role of insulin resistance as an important contributor to CMM development, consistent with previous studies [40–42]. The CHG index, which reflects dysregulation of cholesterol and glucose metabolism, showed weaker and less consistent associations with CMM risk after full adjustment, although evidence from a previous Chinese cohort study reported a positive association between CHG and cardiovascular risk [23]. The CTI index, which integrates glucose, triglycerides, and C-reactive protein, showed significant associations across quartiles, consistent with the findings of Zheng et al. [43], highlighting the combined metabolic and inflammatory burden involved in CMM development. These differences may reflect distinct biological pathways: TyG may capture cumulative metabolic stress related to insulin resistance, CHG may reflect threshold effects of glucose and lipid dysregulation, and CTI may represent the combined effects of multiple metabolic and inflammatory disturbances. It should be noted that certain cardiometabolic conditions, such as hypertension and diabetes, may lie on the causal pathway linking metabolic indices to CMM. Adjustment for such intermediate variables may introduce overadjustment bias and attenuate the estimated associations. Therefore, minimally adjusted models may better reflect the total association between metabolic indices and CMM risk, whereas fully adjusted models may provide estimates closer to the direct association after accounting for potential intermediate factors. Differences in effect estimates across models should be interpreted with caution, as each model addresses a distinct but complementary research question rather than reflecting inconsistency in the findings. It is noteworthy that although categorical and per-SD analyses consistently showed an increased risk of CMM with higher index levels, restricted cubic spline analyses did not reveal statistically significant overall or nonlinear associations. This discrepancy may be attributable to methodological differences: continuous RCS models emphasize the exposure-response pattern and are sensitive to the distribution of data, whereas categorical analyses may better capture risk accumulation at higher exposure levels. Nonetheless, these findings are consistent with prior evidence showing that higher TyG levels are associated with cardiovascular events [44], elevated CHG reflects cardiometabolic burden [45], and CTI, particularly through its representation of atherogenic lipid ratios and lipoprotein metabolism, captures a more comprehensive metabolic burden [46], further supporting the utility of these indices for identifying individuals at elevated CMM risk. There was no evidence of significant interactions between TyG, CHG or CTI and age or sex, indicating that their associations with CMM were stable across demographic subgroups. This suggests broad applicability of these indices in middle-aged and older populations, potentially because aging is commonly accompanied by reduced insulin sensitivity and progressive metabolic dysregulation. Previous studies have shown that age-related impairments in metabolic homeostasis play an integral role in the development of CMM [47]. ROC analyses further showed that CTI had better discriminative performance than TyG and CHG, while composite indices such as TyG-CTI and CHG-CTI achieved slightly higher AUCs than individual indices. Notably, TyG-CTI performed significantly better than TyG alone, suggesting that combining multiple metabolic measures may improve the identification of individuals at high risk of CMM. In contrast, CHG showed relatively weaker discriminative performance, possibly because it primarily reflects cholesterol and glucose imbalance and the proportion of individuals with markedly elevated CHG values may be limited in community-based populations. Overall, the combination of CTI and TyG may be an effective approach for identifying individuals at higher risk of CMM in community settings. Together with their consistent performance across age and sex subgroups, these findings support the potential application of these indices for population-based risk stratification and early preventive strategies. Strengths and limitations This study has several notable strengths. First, the use of the nationally representative CHARLS cohort with 9 years of prospective follow-up enhances the generalizability of the findings and supports temporal inference. Second, CHARLS data were collected using rigorously standardized procedures and included detailed demographic, clinical, and laboratory information, which improved data quality and reliability. Third, the study systematically compared three metabolic indices and their composite indices for CMM risk assessment, which may help identify more informative early risk markers and improve the clinical utility of risk stratification. Finally, multivariable models were used to adjust for potential confounders, and subgroup analyses were conducted to examine the consistency of the associations, thereby strengthening the credibility of the results. Nevertheless, several limitations of this study should be acknowledged. First, because of its observational design, residual confounding cannot be fully excluded, particularly from factors not comprehensively captured in CHARLS. Second, most metabolic and inflammatory markers were measured only at baseline, which may not accurately reflect subsequent biological changes and could introduce regression dilution bias, potentially attenuating the observed associations. Third, loss to follow-up among some participants may have introduced selection bias. Fourth, the study population consisted of middle-aged and older Chinese adults; therefore, caution is warranted when generalizing the findings to younger populations or other ethnic or geographic populations. Additionally, this study focused primarily on metabolic indices and did not include genetic information, detailed lifestyle factors, or other potential determinants of CMM. Future studies should develop and validate more comprehensive prediction models to improve the accuracy of CMM risk assessment. Conclusion Based on a nationwide prospective cohort study, these findings provide evidence linking metabolic indices to the risk of CMM. Higher TyG and CTI indices were independently associated with an increased risk of CMM, underscoring their potential value in the early identification of high-risk individuals. These results suggest that metabolic indices may support risk assessment and targeted prevention strategies, thereby contributing to personalized prevention and management of CMM, healthier aging, and a reduced societal disease burden. Furthermore, the findings provide a basis for future studies aimed at refining prediction models based on metabolic indices and enhancing their applicability in CMM risk stratification. Supplementary Information Supplementary Material 1. Acknowledgements We sincerely thank Professor Xiong for his invaluable guidance and support. Authors’ contributions YJ: Design, Writing manuscript; ML: Conduct, Writing manuscript; HC: Conduct, Analysis; FZ: Conduct, Analysis; SL: Conduct; XL: Conduct; TG: Conduct; ZX: Analysis; QS: Conduct; XX: Design. Funding This work was supported by the 2023 Chinese Nursing Association Scientific Research Project (Project Contract No. ZHKY202321) entitled Construction and Application of a Precision Profiling Platform for Volume Status During the Vulnerable Phase in Heart Failure Patients with Hyponatremia. Data availability The information used in this work is on the CHARLS website. Declarations Ethics approval and consent to participate The research protocol was reviewed and endorsed by the Biomedical Ethics Committee at Peking University (IRB00001052-11014). Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The information used in this work is on the CHARLS website.